Experts discussed ways to ensure drug availability in CIS countries as part
of the business programme of the Healthy Life Forum, which is taking place at
Tauride Palace in St. Petersburg. The event is being organized by the
Roscongress Foundation’s Healthy Life project and the Ministry of Health of the
Russian Federation and is being held with the support of the Interparliamentary
Assembly of CIS Member Nations, the Government of the Leningrad Region, and the
Ministry of Industry and Trade of the Russian Federation.
The meeting was moderated by Association of Russian Pharmaceutical
Manufacturers General Director Viktor Dmitriev.
“The pharmaceutical market of CIS countries is developing rapidly, and
organizing drug availability for citizens is a top priority and a focus of the
state. Developing partnerships, scaling up best manufacturing practices, and
creating a unified legal framework to support pharmaceutical industries will
provide a synergistic effect and a powerful impetus for development,” Dmitriev
said.
The best way to actively
develop the pharmaceutical market of CIS countries in order to meet the modern
needs of healthcare systems for innovative medical products is to implement
synergistic development models, ensure cooperation between industries, and
transfer advanced production technologies. The most important components for
such development are effective state support measures for the pharmaceutical
industry, models to ensure sustainable demand for popular drugs, and scalable
experience in integrating individual industries.
The session was attended by Director of the Russian Federal Service for
Surveillance in Healthcare Alla Samoylova, Director of the Department for the
Development of the Pharmaceutical and Medical Industry of the Russian Ministry
of Industry and Trade Dmitry Galkin, General Director of the Scientific Centre
for the Expert Evaluation of Medicinal Products of the Russian Ministry of Health Valentina Kosenko,
President of the Association of Clinical Pharmacologists of St. Petersburg Alexander
Khadzhidis, General Director of Moscow Endocrine Plant Mikhail Fonarev, PSK
Pharma General Director Yevgenia Shapiro, Chairman of the Board of Kazakhstan’s
SK-Pharmacy Yerkhat Iskaliev, Geropharm General Director Pyotr Rodionov, and
R-Pharm Director for the Strategic Development of Production Assets Yelena
Sinchenko.
“Cooperation between business and the government always provides good
results in the manufacturing sector. The results of cooperation in the
pharmaceutical industry are seen particularly quickly. As part of the
implementation of the Pharma-2020 federal target programme, many enterprises
have appeared in Russia that produce drugs that are in demand among the medical
and patient community, in particular, our company PSK Pharma. In a short time,
the pharmaceutical industry has been able to meet patients’ demand for
technologically complex, globally recognized, and effective high-quality drugs
and organized their production at a high level. Various grants for scientific
developments help to accelerate the R&D process and introduce vital
medicines to the market, while ensuring the country’s drug security. Companies
are investing in promising and socially significant areas and creating new
jobs. This combination provides a powerful synergistic effect, stimulates the
development of the industry, and guarantees reliable drug supplies to patients
today and in the future. Now the industry is actively working to deepen the
production cycle and create its own substances. For example, our enterprise,
with the support of the Federal Development Fund of the Russian Federation and
the Government of the Moscow Region, is setting up import-substituting
manufacturing of substances for genetically engineered biotechnological
preparations,” Shapiro said.
During the meeting, the experts discussed what the pharmaceutical market of
the CIS is really like, what measures are being taken to support the
pharmaceutical industry, what is the role of generic drugs on the CIS
pharmaceutical market, what role does the transfer of innovative medical
technologies play, how to ensure demand for popular medicines, what the
benefits are of introducing a system to label and monitor the movement of drugs
for the pharmaceutical market, and what role cooperation plays in creating
models for the transfer of innovations and bringing them to the CIS markets?
Official website of the event: forumhealth.ru
Telegram channel: t.me/healthy_project